Introduction

Obesity and diabetes have become a global epidemic. A significant proportion of people are diagnosed with diabetes in both developing and developed countries (1,2). In 2015, approximately 30 million American adults had diabetes, representing nearly 10% of the entire U.S. population, with most of the patients diagnosed with type 2 diabetes (3). Data from the National Health and Nutrition Examination Survey (NHANES) show that rates of obesity in the U.S. have increased dramatically since the 1960s, with prevalence of obesity of 35% in 2012, and globally representing nearly 2 billion adults (4,5). Rates of obesity are expected to increase over the next 20 years (6), and more than 80% of adults will be either overweight or obese by the year 2048 (7). Given that obesity is a major risk factor for diabetes, it is not surprising that the rates of type 2 diabetes have also increased, closely mirroring those of obesity. Although type 2 diabetes is traditionally regarded as an adult onset condition, there is increasing prevalence among children and adolescents (8), largely attributed to increased rates of obesity early in life (9).

Diabetes is associated with an increased risk of several cancers, particularly malignancies of the colorectum, endometrium, and breast (10-16). Furthermore, diabetes may also affect cancer prognosis and overall mortality (17-21). The relationship between cancer and diabetes is complex, with shared risk factors such as pro-
inflammatory effects of excess adipose tissue (22-24). Additionally, hyperinsulinemia and insulin resistance, as well as hyperglycemia have been proposed as independent mechanisms linking diabetes with increased risk of malignancies (25).

Another important risk factor for cancer is age. Aging is characterized by an accumulation of genetic alterations. It is also a state of chronic inflammation and a decline in immunity (26), which may be accelerated by obesity (27). Age related changes in the immune system are associated with multiple pathological processes underlying malignancy development (28) (Figure 1).

In this review, we will summarize recent evidence for the associations between diabetes, obesity, aging, and cancer. We performed a PubMed search, restricting to English language publications in November 2019 using these search terms: “Neoplasm or Cancer”, “Obesity”, “Diabetes” AND “Aging”. Reference papers were individually reviewed by the authors.

** Obesity and cancer**

**Obesity is associated with increased risk of cancer**

Overweight is defined as body mass index (BMI) of 25.0 to 29.9 kg/m² whereas obesity is defined as BMI of ≥30 kg/m². While non-obesity related cancers have decreased in the 21st century, obesity related cancers have increased (29). Obesity is an independent risk factor for 13 types of cancer, shown by the International Agency for Research on Cancer (IARC) (30). Examples include endometrial, postmenopausal breast, renal cell, colorectal, gastrointestinal, and pancreatic cancer (31-34). A prospective study showed that in 2014, obesity related cancers accounted for 40% of all cancers (35), and these malignancies are more commonly observed among women than men, older individuals (age >50), and non-Hispanic African Americans (35,36). Multiple studies across different populations have found that women are disproportionately affected by obesity related cancers, with some studies showing that the population attributable fraction of cancer for women is approximately twice as high as men (37,38). This difference likely reflects the strong association between obesity and female cancers including endometrial, ovarian, and breast cancer.

Certain cancers show stronger associations with obesity than other cancer types—colorectal cancer (relative risk, RR 1.3–1.4), postmenopausal breast cancer (RR 1.1–1.2), and endometrial cancer (RR 6.3–8.1) (30). Obesity is correlated with increased risk for different subtypes of postmenopausal breast cancer including both estrogen receptor (ER) and progesterone receptor (PR) positive breast cancer (39-42) as well as triple negative breast tumours (43). While obesity is a strong risk factor for postmenopausal breast cancer (44,45), increased weight early in life may confer a lower risk of premenopausal breast cancer (46-48). Previous studies including a large study which included over 750,000 premenopausal women found that younger women with higher BMI had a lower risk of premenopausal breast cancer compared to those with lower BMI (49,50). However, it is unclear whether this...
association is seen across all ethnicities. For example, an older systematic review found that obesity was correlated with increased risk of both pre and postmenopausal breast cancer in women of Asian descent (51). However, this was not replicated by other studies. Future studies are required to elucidate the mechanisms by which obesity may confer a protective effect against breast cancer development among younger, pre-menopausal women and to better understand the effect of obesity on risk of breast cancer development amongst different ethnic groups.

Interestingly, in prostate cancer, the relationship between obesity and cancer risk is less clear. One study found that a high BMI may correspond to a lower risk of cancer but an elevated waist circumference may correlate with a higher risk (52), whereas a pooled analysis found a higher BMI was associated with increased risk for advanced prostate cancer (53). These discordant findings may reflect methodological variations and differences in study populations. However, they may also highlight the limitations of using BMI as a surrogate marker for adipose tissue given that it does not differentiate muscle from fat mass, nor site of adiposity. Furthermore, some authors have demonstrated that waist circumference, which provides a better estimate of visceral adiposity than BMI may be more indicative of prostate cancer risk than BMI alone (54-56).

**Possible mechanisms linking obesity and cancer**

Multiple hypotheses have been proposed as possible mechanisms linking obesity with development of cancer. First, obesity is linked to a state of chronic inflammation (57,58). Pro-inflammatory cytokines may enhance tumour cell proliferation, angiogenesis, and invasion into healthy cells, metastasizing into distant organs (59). In breast cancer, for instance, higher levels of cytokines such as tumour necrosis factor (TNF-alpha) and interleukin (IL-6) among obese patients are positively correlated with progression of tumour (60). In addition, epidemiological data show that rates of cancer are increased among patients with chronic inflammatory conditions, leading to the hypothesis that inflammation may contribute to neoplasm development (61).

Second, adipokines such as adiponectin and leptin, which are hormones derived from adipose tissue may play an important role in cancer formation. Adiponectin regulates glucose metabolism and fatty acid oxidation, and it is inversely correlated with BMI. In vitro models have shown that adiponectin may have protective effects against carcinogenesis in breast, endometrial, colon, and prostate cancer (62-65). Leptin is mostly produced by adipocytes to induce satiety and reduce hunger. Leptin deficiency is a rare cause of severe obesity, which typically arises in childhood (66). More commonly, leptin levels are higher in individuals with obesity compared to normal weight individuals. Individuals with obesity exhibit leptin resistance, similar to insulin resistance in type 2 diabetes (67). Higher leptin levels are associated with increased cancer risk (68). Preclinical studies have shown that leptin is involved in inflammatory, mitogenic and pro-angiogenic pathways in breast cancer development (69). One study found that inhibition of leptin signaling reduced the growth of carcinogen-induced breast cancer (70).

Third, high adiposity is associated with increased serum estrogen, as estrogen production is increased through peripheral aromatization of androgens via aromatase activity in adipose tissues. Excess estrogen can promote tumour development through DNA damage, angiogenesis, and cellular proliferation (71,72). There are ERs on certain obesity related tumours such as breast and endometrial cancer. This may explain the finding that postmenopausal women with a higher BMI have been shown to have an increased risk of ER and PR positive breast cancer (44). An analysis of eight prospective studies showed that the risk for postmenopausal hormone positive breast cancer is at least partially attributable to increased estradiol levels (73). On the other hand, the protective effect of earlier onset obesity on pre-menopausal breast cancer development is not well understood but the inverse relationship between obesity and pre-menopausal breast cancer risk is primarily seen with ER positive tumours rather than ER negative tumours, suggesting a hormonally mediated pathway. Previous studies have postulated that the estrogenic effect of obesity in adolescence may lead to higher levels of tumour suppression genes, therefore reducing the risk of breast cancer development. Furthermore, it has been speculated that high levels of estrogen due to aromatase action in fat tissue may shut off the hypothalamic/pituitary/ovarian axis, resulting in amenorrhea, which is a known protective factor against breast cancer formation (49). However, this has not been a consistent finding in the literature, therefore further studies are required to further characterize the relationship between timing of obesity onset and breast cancer risk.
Obesity may confer worse cancer prognosis and increase treatment related complications

Obesity may be a negative prognostic factor for cancer recurrence and survival for a variety of cancer types. It is estimated that each 5% increase in BMI is associated with a 10% increase in cancer related deaths (74). Higher BMI has been shown to increase the risk of rectal cancer and breast cancer recurrence (75,76), and worse survival in pancreatic (77,78) and colon cancer (79,80). Death from multiple myeloma is 50% more likely for obese individuals as compared to lean individuals (81). A recent meta-analysis including 82 studies involving over 200,000 breast cancer patients found that overall and cancer specific mortality was increased among women with obesity with a relative risk of 1.41 (95% CI, 1.29 to 1.53) and 1.35 (95% CI, 1.24 to 1.47), respectively, compared to women with normal weight (82). Several studies have shown that obese patients present with larger breast tumours, with a subset of studies showing that breast cancer may be more advanced at the time of presentation (83,84). This may be partially due to lower cancer screening among women with obesity (85,86), lower detection of smaller tumours, and barriers in accessing screening and appropriate follow up secondary to obesity associated stigma and competing care demands (87). In addition, breast tumours in women with obesity may be more biologically aggressive, resulting in higher risk of recurrence and mortality, with the strongest evidence shown for ER+ cancer (88–90). Furthermore, endocrine or chemotherapy may be less effective in obese patients compared to patients with normal weight, despite appropriate doses of chemotherapy (91), possibly through JAK2/STAT3 mediated chemoresistance (92).

Obesity has also been found to be associated with an increased risk for treatment-related complications. In breast cancer, for instance, obese patients are at higher risk for anesthesia related complications and are more likely to experience respiratory difficulty in the perioperative setting (93). Rates of lymphedema are also higher in breast cancer survivors (94,95). In a multicenter Italian study, obesity was associated with a higher risk of incontinence in prostate cancer survivors treated with radical prostatectomy (96). A population-based Dutch study of patients with colorectal cancer undergoing surgery showed that obesity was a major determinant for post-operative complications, increased length of stay, and greater readmission risk (97).

Impact of weight loss on cancer risk and mortality

Weight loss may be associated with a decreased risk of the developing obesity related cancers. The Iowa Women's Health Study showed that women with 20 pound or more weight loss had a 14% reduction in risk of obesity related cancers, including breast, colon, and endometrial cancers (98). Similarly, in the Women's Health Initiative cohort, weight loss among women with obesity was associated with a 54% lower risk of endometrial cancer (99). A recent large, prospective U.S. cohort study, which consisted of over 58 000 post-menopausal women aged 50–79 years, found a significant reduction in incidence of obesity related cancers among women who intentionally lost 5% or more of their body weight during a 3-year study period (100). Weight loss achieved through bariatric surgery has also been shown to be associated with an approximately 40% reduction in obesity related cancers after 3.5 years of follow up (101). It is important to keep in mind that it is possible some of the reduced cancer risk may be due to lifestyle optimization and changes in behavioural factors, such as diet and physical activity (102,103), rather than weight loss itself. Nonetheless, these findings are encouraging and suggest that even a relatively modest weight loss may be beneficial for cancer risk reduction. Given that few studies have systematically examined the effect of weight loss on cancer risk in men, future efforts to study this population would be helpful.

Existing literature on the effect of weight loss on cancer outcomes is sparse; most of the data come from the breast cancer literature. For example, the Women’s Intervention Nutrition Study randomized 2,437 women with stage I to III breast cancer to either standard care or a low-fat diet. The intervention group lost a mean of 6 pounds in body weight, and after a period of 5.6 years, disease-free survival was higher in the intervention group as compared to the standard care group (hazard ratio 0.76, 95% CI, 0.60 to 0.98) (104). However, these findings lost statistical significance during follow up, possibly due to decreased diet adherence during this period (105). The more recent SUCCESS-C trial randomized women with stage II and III breast cancer first to one of two chemotherapy treatments, then assigned those with BMI 24 to 40 kg/m² to either a weight loss intervention or standard care (106). Interim analysis showed that participants in the weight loss group had a mean weight loss of 1 kg while the control group gained an average of 0.95 kg over the study period. While
there was no difference for either disease-free or overall survival between the groups in intention-to-treat analyses, women who completed the weight loss intervention had better disease-free survival compared to those who left the intervention group (hazard ratio 0.35, 95% CI, 0.27–0.45). The high drop-out rate of more than 50% in the weight loss group compared to 20% in the control group makes these findings difficult to interpret. Large, well conducted studies are needed to provide definitive evidence for the impact of weight loss on survival following cancer. Such studies are underway for breast cancer (106,107), and are needed for other obesity related cancers.

**Diabetes and cancer**

**Diabetes and cancer risk**

Earlier epidemiologic studies showed that type 2 diabetes may be associated with an increased risk of pancreatic cancer, colorectal cancer, breast cancer, and cholangiocarcinoma (108-111). However, these early observational studies did not properly adjust for confounders and were prone to detection bias and protopathic bias and may have overestimated initial risk estimates (10). More recent epidemiologic studies in this area have used statistical methods to minimize these biases (112,113). A recent, large meta-analysis found consistent associations between diabetes and increased risk for certain cancers such as malignancies of the colorectum (pooled RR of 1.27, 95% CI, 1.21–1.34), breast (pooled RR of 1.20, 95% CI, 1.12–1.28), and endometrium (pooled RR of 1.97, 95% CI, 1.71 to 2.27) (16). A recent European cohort study found that diabetes correlated with increased risk of gastrointestinal cancers even after applying a 1-year lag period to adjust for detection bias (114). The association between diabetes and increased risk of renal, pancreatic, hepatocellular, gastric, and thyroid cancers is more uncertain due to methodological limitations and heterogeneity of previous studies.

There is also evidence for an increased cancer risk even prior to the diagnosis of diabetes, a period that is marked by hyperinsulinemia and insulin resistance. A U.S. study found a 16% increased risk of breast cancer in the 10 years prior to onset of type 2 diabetes, and a 28% increased risk for colorectal cancer in men before diabetes diagnosis (115). Our group found that patients with diabetes had a 23% higher risk of being diagnosed with cancer in the 10 years prior to a clinical diagnosis of diabetes (116). These findings suggest a possible role for hyperinsulinemia in oncogenesis (to be discussed further in “Mechanisms linking diabetes and oncogenesis”).

Interestingly, as with obesity, diabetes may be protective against prostate cancer. A meta-analysis found a 14% lower risk of prostate cancer among patients with diabetes (117,118). Some of the postulated mechanisms for this inverse relationship include (I) lower circulating testosterone levels among patients with diabetes and therefore decreased stimulation of the prostate (119); (II) detection bias secondary to fewer diabetes men getting prostate biopsies, even with elevated PSA (120). While previous studies have also suggested that anti-diabetic medications may have a protective effect against the development of prostate cancer (121), this was not supported by a recent large European population based study (120).

Given that obesity is frequently associated with type 2 diabetes, it important to isolate the effect of diabetes on cancer risk apart from that of obesity. It has been shown that obese woman with diabetes have a higher risk of endometrial cancer than those with diabetes alone (122). In a large meta-analysis, Pearson-Stuttard et al. estimated the global cancer burden attributable to diabetes alone versus diabetes and obesity combined, and found that in 2012, 6% of all incident cancers were attributable to the combined effects of diabetes and obesity. Obesity alone (3.9% of all new cancer cases) was responsible for almost twice as many cases of cancer as diabetes (2.1% of all new cancer cases) globally (123), indicating that obesity may be the more important contributory factor than diabetes in its impact on cancer incidence.

There are fewer studies that have examined the association between type 1 diabetes and cancer risk. A large European population based study showed a slightly higher risk of cancer among female patients with type 1 diabetes, with a hazard ratio of 1.07 (95% CI, 1.04, 1.10) among women and 1.01 (95% CI, 0.98, 1.04) among men (124). The increased risk was seen for gastric, liver, endometrium and kidney tumours, and a reduced risk for prostate and breast cancer. Interestingly, risk of cancer was highest around the time of diabetes diagnosis, which suggests a possible role for detection bias in this association. Another more recent meta-analysis of 15 observational studies and 13 cohort studies found the same decreased risk of breast cancer among patients with type 1 diabetes (125). Overall, the mechanism for this possible association remains unclear. Future studies are required to further elucidate the relationship between type 1 diabetes and breast cancer.
Mechanisms linking diabetes and oncogenesis

The pathophysiology of type 2 diabetes involves development of hyperinsulinemia in response to insulin resistance, which eventually results in hyperglycemia (126). Over time pancreatic beta cells undergo apoptosis, leading to decreased beta cell mass and clinical manifestations of type 2 diabetes. Prospective studies have shown that hyperinsulinemia may occur as early as 18 years prior to the diagnosis of diabetes (127).

It is well established that hyperinsulinemia is associated with higher risk of breast, colorectal, and endometrial cancer (128,129). Insulin may lead to oncogenesis via several mechanisms. Insulin exerts its effect through the action of IGF1 and IGF2, which have critical roles in cell survival and proliferation. IGF1 is expressed in prostate tumours and promotes androgen responsive prostate cancer growth (130), even in a growth hormone suppressed state. IGF-1 receptor plays an important role in the pathogenesis of multiple myeloma through its effect on the receptor tyrosine kinase FLT3 (131) and the fusion oncoprotein MLL-AF9 (132), which contributes to the malignant transformation of hematopoietic progenitor cells. IGF-1 levels are higher among patients with more advanced CRC compared to those with less advanced CRC (133). An in-vitro study demonstrated that activation of IGF-1/STAT3 signaling increased colorectal cancer formation and that inhibition of this pathway reduced tumour burden (134). Higher IGF-1 levels may indicate higher risk for recurrence in breast cancer (135). In addition to IGF-1 mediated pathways that may contribute to carcinogenesis, IGF-2 can also promote tumour development through insulin receptor (IR-A). Novosyadlyy et al. (136). observed the acceleration of breast cancer development through IR mediated pathways that could be reversed by inhibition of IR signaling in mice. Similarly, Lu et al. showed proliferation of CRC cells via IR signaling and downstream increase in PI3K/Akt and MAPK activation (137).

It is unclear whether hyperglycemia by itself is an independent contributor to cancer growth or whether it exerts indirect effects through hyperinsulinemia, IGF, IR, and inflammatory cytokines. It has long been postulated that cancer cells have increased glucose uptake and uses glucose as fuel for proliferation due to damaged mitochondria in cancer cells, known as the Warburg effect (138,139). Poor glycemic control has been shown to increase levels of advanced glycation end products (AGE) which activate receptors to bind inflammatory cytokines that are involved in oncogenesis (140). In a large systematic review of 35 studies, Xu et al. (141) found that HOMA-IR, which is a measure of insulin resistance, was a better predictor of CRC risk than fasting glucose and fasting insulin. However, markers of long-term glycemic control such as glycated hemoglobin (A1c) also correlated with CRC risk, albeit this was a weaker predictor of cancer risk. Given this study included mostly case-control studies, future prospective studies are required to better understand the effect of glycemic control as an independent risk factor for cancer development. In contrast, a recent population-based cohort study showed that overall, A1c had no association with risk of certain cancers such as malignancies of the colorectum, breast, lung, and liver (HR 1.0, 95% CI, 0.98–1.02 for all sites) (142). In summary, it is difficult to disentangle the individual effect of glycemic control from other aspects of metabolic syndrome on cancer risk. Well designed, prospective studies are needed to definitively answer this question in the future.

Diabetes and mortality

Evidence indicates that patients with diabetes have higher mortality rates after cancer diagnosis. Many older studies did not adjust for stage at cancer diagnosis or take into account competing risks, and were not designed to separate overall mortality from cancer specific mortality. We have shown in CRC that comparing to patients without diabetes, those with diabetes had a modestly increased overall mortality (adjusted hazard ratio of 1.08, 95% CI, 1.04, 1.12), but a similar CRC specific mortality (143). We did find a trend towards increased CRC-specific mortality among patients with diabetes of at least 2 years compared to those with recent onset diabetes. Similarly, a recent population based U.S. study among older adults (age >67 years) showed that there was a small increase in CRC-specific death among diabetes patients with diabetic complications (144). A large pooled analysis of 97 prospective studies showed that diabetes was associated with a moderately increased risk of cancer specific death from multiple cancers, including breast cancer (145). In addition, our group showed that, in patients with diabetes and breast cancer, cancer-specific mortality was increased only among those with longer diabetes duration and cardiovascular disease (21). These data indicate that chronicity of metabolic derangement and comorbidities may be important prognostic factors for cancer specific survival among individuals with diabetes.

In contrast, diabetes has consistently been shown to be
associated with increased all-cause mortality after a cancer diagnosis, particularly for colorectal, breast, and endometrial cancers (18–20,146,147). For instance, Barone et al. (148) found that all-cause mortality was increased in diabetes patients with CRC (pooled HR of 1.32, 95% CI, 1.24, 1.41), endometrial cancer (pooled HR of 1.76, 95% CI, 1.34–2.31), and breast cancer (pooled HR of 1.61, 95% CI, 1.46–1.78). Similarly, a more recent U.S. population based study showed that in older adults, pre-existing diabetes increased overall mortality among patients with CRC (HR 1.2, 95% CI, 1.17, 1.23) (20). The discrepancy between cancer-specific and overall mortality has been largely attributed to increased risk of cardiovascular deaths in patients with diabetes (20,149). These results indicate that optimization of non-cancer care is important in improving outcomes for patients with diabetes and cancer.

**Aging and cancer**

**Age is a risk factor for cancer development**

Age is a risk factor for both cancer and diabetes. A U.S. national survey in 2017 showed that among U.S. adults, the prevalence of diabetes was 2.9% among those aged 20–44 years, 12.4% among those aged 45–64 years, and 19.8% among those older than 65 years of age (150). The incidence of diabetes in the U.S. in 2015 was 3.1 per 1,000 for age 18–44, 10.9 per 1,000 for age 45–64, and 9.4 per 1,000 for those older than 65 years of age (151).

Risk of cancer also tends to increase with age. Recent population-based data from the U.S. Surveillance Epidemiology and End Results (SEER) database in 2015 indicated that the median age of cancer diagnosis was 66 years, with 25% incident cancer diagnosed among those between 65 to 74 years of age (152). The median age at diagnosis was 61, 68, 70, and 66 years for breast, colorectal, lung, and prostate cancer, respectively (152). Among cancers diagnosed during this period, 5.2% were among those aged 35–44 years, 14.1% among those aged 45–54 years, 24.1% among those 55–64 years, and 25.4% among those aged 65–74 years (152).

While rates of certain cancers have decreased overtime, the overall rates of new cancer cases rose between 1975 and 2015 in the U.S. (153) Cancer incidence is expected to rise in the coming decades. In 2015, the Canadian Cancer Society reported that the incidence of cancer is expected to rise by 40% over the next 15 years (154). One contributing factor is rising age. The median age of the Canadian population was 26.2 years in 1971, 39.5 years in 2009, which is projected to rise to between 42 and 45 years by 2036. In 2036, about 25% of all Canadians will be seniors (age > 65 years) (155). Another contributing factor is the rising rates of obesity (4–7). Some of the most common types of cancer such as breast and colorectal cancer are obesity associated cancers (156). Not only do rising rates of obesity contribute to increased cancer rates, they also lead to increased rates of diabetes (4). Coupled with an aging population, higher rates of obesity and diabetes further add to the burden of cancer in the population.

**Mechanisms of carcinogenesis in the aging individual**

An accumulation of mutations is a major theory for mechanisms of aging and plays an important role in the pathogenesis of many malignancies (157). An increase in somatic mutations with age has been documented in a variety of target genes, such as T-cell receptor (158), using various techniques such as chromosome painting and single nucleotide polymorphism (SNP) arrays (159–162).

An analysis of several genome-wide association studies (GWAS), which included more than 100,000 patients found that the presence of large leukemia-associated chromosomal abnormalities increased with age (161). Nair et al. demonstrated age related increase in driver mutations such as PIK3CA, KRAS, and PTEN in women with endometrial cancer (163). These genetic aberrations do not remain static, and are modulated by several environmental factors, such as smoking, infections, and toxin exposures overtime (164,165).

Aging is associated with a chronic, low-level inflammation, known as “inflammaging” (26), which contributes to the development of cancer. Cytokine production in response to Toll-like receptor (TLR) activation is significantly increased with aging. Hearps et al. showed that aging is associated with a persistence in TLR activation following West Nile virus infection in monocytes from older individuals (166). In a cross-sectional study of over 800 patients, age 85 or older, Collerton et al. (157) found a positive correlation between inflammatory markers including IL-6, TNF-alpha, CRP and frailty, defined using Fried and Rockwood models, which are two commonly used measurements of frailty. It has also been shown that dendritic cell production of anti-inflammatory cytokines such as IL-12 and IL-10 is reduced among older individuals (167).

Inflammation and carcinogenesis are two interconnected
processes. Inflammation may trigger genetic mutations or epigenetic changes, resulting in carcinogenesis (168). Inflammatory cells interact with tumour cells and surrounding stroma to create an immunosuppressive tumour microenvironment, allowing for cancer progression and metastasis (162,169). A proinflammatory environment also leads to worse cancer prognosis in triple negative breast cancer (170), Hodgkin’s lymphoma (171), and colorectal cancer (172). Aging is also associated with immunosenescence, a process characterized by a reduction in B and T cell proliferation and function, as well as loss of immune regulation, which plays a vital role in age related decline of antitumor immunity (157). Although inflammation is recognized as an important player in tumour formation and progression, a better understanding of the complex interactions between inflammation and immunity is required to improve current immunotherapy strategies and cancer-related outcomes.

Worse cancer outcomes among older patients with cancer

There is epidemiological evidence to suggest that older patients have worse net cancer survival compared to younger patients, even after adjusting for mortality from non-cancer causes (173). In men, the largest age gaps in survival were found for lymphoma, multiple myeloma, and leukemia. For women, the largest age gaps in survival was shown for brain cancer, ovarian, cervical cancer, and multiple myeloma. These age-related differences in survival likely reflects both biological factors as well as differences in healthcare use and delivery between older and younger patients. One of the most important determinants of survival is stage at diagnosis. For instance, it has been shown that individuals age 85 or older are more likely to present with later stage disease compared to those who are 65 to 84 years of age (174). Breast and colorectal cancer patients older than 85 years of age are 10% are more likely to present with more advanced cancer compared to adults between ages 65 to 84 (174). Taken together, these findings indicate that older adults may present with more advanced cancer at the time of diagnosis, which may lead to worse survival outcomes.

Selecting the appropriate cancer treatment in the older adult requires careful consideration, given the multiple medical comorbidities that many elderly patients face. Previous studies showed that older patients with breast cancer are less likely to receive evidence based medical care, even after adjusting for medical comorbidities (175,176). Using the U.S. SEER database, LeMasters et al. found that patients older than 75 years of age were approximately 40% less likely to receive guideline-based care, suggesting possible under-treatment of cancer among the elderly (175). However, this may be clinically appropriate in an older, frail individual who may not be able to tolerate cancer treatment. In fact, the same authors found that the presence of certain concurrent chronic conditions such as diabetes and heart disease reduced the likelihood of receiving guideline-based care, due to physician concerns regarding increased risk of treatment complications (176,177). While it is important not to over-treat this vulnerable population, it is equally important not to stereotype all older adults as frail, who will invariably deteriorate and lose their independence (178). Older adults are a heterogeneous population. Chronological age does not necessarily equal biological age, and may not reflect underlying immune function and degree of immunosenescence (179). Given that most clinical trials have traditionally excluded older adults from participating, there is a need for age-specific clinical studies to provide better evidence based clinical decision making tools to improve cancer care for older adults with cancer (180,181).

Aging in cancer survivors

Cancer (179,182) and cancer treatments may accelerate the aging process. Aging is characterized by a gradual accumulation of cellular damage leading to dysregulated organ function (183). Systemic cancer therapies and radiation accelerate aging by increasing inflammation (184), inducing immunosenescence (185,186), causing DNA damage and decreasing telomere length (187-189). Examples of chemotherapies that promote aging include alkylating agents, such as cyclophosphamide, anthracyclines, such as doxorubicin, topoisomerase inhibitors, such as irinotecan, antimetabolites/cytotoxic drugs such as 5-FU (190).

Furthermore, some of these agents can also cause organ damage, as in the case of doxorubicin related cardiotoxicity, which further adds to frailty and the aging process among cancer survivors (190). Long term follow up studies of childhood cancer survivors show that these patients have higher rates of functional loss, frailty, medical comorbidities and cognitive decline, with much earlier onset than healthy controls (191-193). Specifically, adult survivors of childhood cancer were three times more likely to have a chronic condition, and 8 times more likely to have a severe condition and nearly all have at least one chronic medical condition by age 50 (194,195). Recognition of these late effects have led to efforts to improve cancer treatments to
reduce their associated toxicity. Follow up data from the Childhood Cancer Survivor Study cohort demonstrated that overall, the 20-year cumulative incidence of at least one significant chronic condition has decreased from 33% to 27% patients treated from 1970–1979 compared to 1990–1999 (196). Longitudinal studies to determine aging trajectories among childhood cancer survivors, and mechanistic studies to characterize the pathways that lead to accelerated aging are underway, and will help to inform strategies to optimize health of the aging cancer survivor.

A 2016 study (197) using SEER data found that among adult cancer survivors, the most common comorbid conditions were congestive heart failure (6–20% depending on age of the survivor), chronic obstructive pulmonary disease (17–21%) and diabetes (23–28%). The distribution of comorbidities differed by cancer site such that patients with lung cancer had much higher rates of certain conditions such as CHF and COPD, likely reflecting tobacco use as a common risk factor for both lung cancer and cardiac and other respiratory comorbidities. Interestingly, there was no significant difference in the burden of comorbidities among individuals in the same age category when stratified by cancer status. For instance, 23% of adults without cancer aged 80–84 years had diabetes whereas 27% of adults with cancer in the same age category had diabetes. This lack of difference in rates of comorbidities between the two populations may be due to a selection bias. Healthier cancer patients likely have a survival advantage as compared to cancer patients with greater baseline comorbidities and therefore may be more similar to the non-cancer patients.

**Cancer in younger adults**

While overall, the risk of cancer increases with age, certain cancers are more likely to be diagnosed among younger than older individuals. For instance, bone cancer is most frequently diagnosed among those younger than 20 years of age. Neuroblastomas are more common in children than adults (152). Furthermore, there is emerging evidence showing that rates of certain cancers have disproportionally increased among younger adults aged 25–49 years (198), with the largest increase in cancers associated with obesity. A recent epidemiological study in the U.S. found that from 1995 to 2014, there was an increase in the incidence of 12 obesity-related cancers, such as multiple myeloma, colorectal, uterine, gallbladder, kidney and pancreatic cancer among young adults age 25–49 years (198). During this period, obesity prevalence in the U.S. has also increased by more than 100% among children and young adults (199). Data from other westernized countries have also reported that rates of colorectal, gastric, and endometrial tumours are rising among young adults across the world despite stable or decreasing rates of these cancers in other age groups (200-205). Even more concerning, mortality rates for colorectal cancer have also increased among Caucasian individuals aged 30–39 since 1995 and for those aged 40 to 54 years since 2005 in the U.S., closely mirroring the increased incidence rates during the same period (206). In the Cancer Prevention Study II, a prospective study of over 1 million American men and women, Jacobs et al. found that every 5 unit increase in BMI was associated with a 25% higher risk of pancreatic cancer-specific mortality in individuals younger than 50 years of age (207). These findings have important clinical implications. For instance, in 2018, the American Cancer Society recommended that for those at average risk of colorectal cancer, routine screening should start at age 45, instead of age 50, given the significant increase in CRC among younger individuals (208). Taken together, much of the trends seen in recent years reflects increasing rates of obesity among young patients, highlighting the importance of early intervention to reduce obesity and associated cancers.

**Conclusions**

In summary, we have highlighted recent evidence on the relationship between obesity, diabetes, aging, and cancer. Overall, excess weight, dysregulated glycemic control, and aging increase the risk of certain cancers. The aging population, together with the epidemic of obesity and diabetes is expected to lead to unprecedented increases in cancer incidence globally. Aging, obesity, and diabetes all have a common risk factors for cancer formation such as inflammation which may be synergistic when co-occurring (168,209). Patients with obesity and diabetes may also have higher rates of treatment and/or cancer related complications, which may confer a worse prognosis. Although age is one of the strongest risk factors for cancer development, there is increasing evidence to show that cancer rates have increased among younger patients, likely due to increased rates of obesity. These observations highlight the importance of early intervention to tackle obesity and to reduce rates of obesity related cancers in both older and younger individuals. Overall, these associations are complex and future studies are required to better characterize the underlying mechanisms to help inform and
guide treatments in those with obesity, diabetes, and cancer.

**Acknowledgments**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**References**

1. International Comparisons: A Focus on Diabetes. CIHI 2015.


164. Forsberg LA, Rasi C, Malmqvist N, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet


Cite this article as: Qiang JK, Lipscombe LL, Lega IC. Association between diabetes, obesity, aging, and cancer: review of recent literature. Transl Cancer Res 2020. doi: 10.21037/tcr.2020.03.14